Prediction of Postoperative Pulmonary Complications in Thoracic Surgery (NCT07359885) | Clinical Trial Compass
Not Yet RecruitingNot Applicable
Prediction of Postoperative Pulmonary Complications in Thoracic Surgery
France100 participantsStarted 2026-06-01
Plain-language summary
Lung cancer is a common disease, and its treatment is lobectomy or pulmonary segmentectomy. In France, approximately 8,000 patients undergo this procedure each year, but it remains associated with significant Postoperative Pulmonary Complications (PPC). This surgical trauma triggers a multicellular and orchestrated immune response, necessary for defense against pathogens, as well as for inflammatory resolution and wound healing. Preoperative single-cell analysis of the patient's immune system is therefore a promising strategy for identifying biomarkers of postoperative pulmonary complications (PPC). Brice Gaudilliere's laboratory at Stanford University, in collaboration with the Paris-based startup Surge, has developed and patented a multivariate model integrating mass cytometry data, proteomic analyses, and clinical data collected before surgery to accurately predict surgical site complications after major abdominal surgery. However, no study has yet explored the identification of inflammatory biomarkers predictive of PPC after thoracic surgery.
Who can participate
Age range
18 Years – 99 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Age ≥ 18 years
* ASA score ≤ 3
* Patients undergoing scheduled video-assisted or robot-assisted lobectomy, bilobectomy, or segmentectomy.
* Patients who have read and understood the information letter and do not object to the research.
* For women of childbearing age (non-sterile): effective contraception
* Menopausal (non-medically induced amenorrhea for at least 12 months)
* Patients covered by a social security scheme
Exclusion Criteria:
* Minor patients
* Surgery scheduled for a Friday
* Patients undergoing a pneumonectomy
* Pregnant or breastfeeding women
* Patients deprived of their liberty by an administrative or judicial decision, as well as those under legal protection, guardianship, or curatorship
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Evaluation of the prognostic performance of a score for screening patients at risk of postoperative pulmonary complications (PPC)
Timeframe: Evaluation of the prognostic performance of a defined score using a machine learning method (STABL: Stability Selection) integrating preoperative immune (cytometric and proteomic) and clinical data within 7 postoperative days of a major lung resection